Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve Audited financial result ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has informed BSE that its Board of Directors will meet on Thursday, May 29, 2025, at the registered office in Ahmedabad. The main agenda item is to consider and approve the audited financial results for the quarter and financial year ended March 31, 2025, along with the Auditor's Report and a certificate for unmodified opinion under SEBI LODR Regulation 33. The meeting also includes a standard agenda item covering any other business with the Chairman's permission. Signed by Director Bhoomi Patel (DIN: 08316893), the filing is a routine regulatory intimation under Regulation 29 ahead of the results announcement. No actual financial numbers, segment data, or dividend declarations are disclosed in this notice.
This is a procedural filing announcing an upcoming results announcement, not the results themselves. Shareholders should watch for the actual audited Q4 and FY25 numbers on or after May 29, 2025, which could move the stock depending on revenue, profit, and the auditor's opinion disclosed.